share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

SEC ·  Aug 30 04:26
Summary by Futu AI
Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 29, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. This transaction is part of an exercise or conversion of a derivative security. Following this acquisition, Gibson's direct holdings in the company increased to a total of 757,656 shares. The transaction is currently in progress.
Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 29, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. This transaction is part of an exercise or conversion of a derivative security. Following this acquisition, Gibson's direct holdings in the company increased to a total of 757,656 shares. The transaction is currently in progress.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.